Literature DB >> 23568107

The pharmacodynamics of rocuronium in pediatric patients anesthetized with halothane.

G Bikhazi1, F Marin, N J Halliday, K Deepika, F F Foldes.   

Abstract

The aim of this study was to determine the neuromuscular blocking potency of rocuronium (ORG 9426) in 4-to 14-year old children anesthetized with halothane. After induction of anesthesia, the ulnar nerve was stimulated with electrical impulses of 0.2 ms duration every 12 s and the force of contraction of the thumb (P) was continuously recorded. Doses of 0.12, 0.16, 0.20, and 0.24 mg·kg(-1) rocuronium were administered, in a randomized fashion, to 4 groups of 12 patients each. The ED50, ED90, and ED95 of rocuronium determined from the log dose-probit regression lines were 0.18, 0.34, and 0.40 mg·kg(-1), respectively. To facilitate tracheal intubation, after the development of the maximal effect of the first dose, a variable second dose of rocuronium was administered to increase the total dose to 0.3 mg·kg(-1). If after the second dose P was greater than 10% of control, additional 0.025-0.1 mg·kg(-1) increments of rocuronium were administered until P became less than 10% of control. At this time the trachea was intubated. Muscular relaxation was maintained with 0.075, 0.1, or 0.125 mg·kg(-1) rocuronium, administered whenever P recovered to 25% of control. The clinical duration of these doses was 6.9±2.8, 6.1±0.4, and 8.1±0.6 min, respectively. On repeated administration of three 0.1 or 0.125 mg·kg(-1) doses, rocuronium showed little cumulative tendency. Time for spontaneous recovery of P from 25% to 75%, 8.4±0.39 min and from 10% to 90%, 16.19±0.15 min, of control, were relatively short. When at termination of anesthesia T4/T1 ratios were lower than 0.75, the residual neuromuscular block could be antagonized with 0.5 mg·kg(-1) edrophonium in 2 min. Rocuronium, 0.3 mg·kg(-1) caused a 13.5% increase of heart rate but had no effect on blood pressure. In conclusion, in 4 to 14-year-old children, rocuronium appears to have a more rapid onset and shorter duration of action than other steroid-type muscle relaxants.

Entities:  

Year:  1994        PMID: 23568107     DOI: 10.1007/BF02514645

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  8 in total

1.  A comparison of the pharmacodynamics of rocuronium and vecuronium during halothane anaesthesia.

Authors:  M G Booth; B Marsh; F M Bryden; E N Robertson; W L Baird
Journal:  Anaesthesia       Date:  1992-10       Impact factor: 6.955

2.  The human cardiovascular response to fluothane anaesthesia.

Authors:  M JOHNSTONE
Journal:  Br J Anaesth       Date:  1956-09       Impact factor: 9.166

3.  Clinical responses to ORG 9426 during isoflurane anesthesia.

Authors:  T J Quill; M Begin; P S Glass; B Ginsberg; M S Gorback
Journal:  Anesth Analg       Date:  1991-02       Impact factor: 5.108

4.  [The neuromuscular blocking effects of ORG 9426].

Authors:  M Mayer; A Doenicke; A Hofmann; R Angster; K Peter
Journal:  Anaesthesist       Date:  1991-12       Impact factor: 1.041

5.  The Relaxometer: a complete and comprehensive computer-controlled neuromuscular transmission measurement system developed for clinical research on muscle relaxants.

Authors:  C J Rowaan; R H Vandenbrom; J M Wierda
Journal:  J Clin Monit       Date:  1993-01

6.  Pharmacodynamic effects of three doses of ORG 9426 used for endotracheal intubation in humans.

Authors:  M Y Dubois; G Lapeyre; D Lea; D Q Tran; B K Kataria
Journal:  J Clin Anesth       Date:  1992 Nov-Dec       Impact factor: 9.452

7.  The neuromuscular effects of ORG9426 in patients receiving balanced anesthesia.

Authors:  F F Foldes; H Nagashima; H D Nguyen; W S Schiller; M M Mason; Y Ohta
Journal:  Anesthesiology       Date:  1991-08       Impact factor: 7.892

8.  Neuromuscular and cardiovascular effects of pipecuronium.

Authors:  F F Foldes; H Nagashima; H D Nguyen; D Duncalf; P L Goldiner
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.